These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33628603)

  • 1. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer.
    Ruan Q; Ding D; Wang B; He C; Ren X; Feng Z; Pang Z; Wang J; Zhang X; Tang H; Wang J; He Q; Lei Z; Liao Q; Luo J; Cui S
    Cancer Biol Med; 2021 Feb; 18(1):308-317. PubMed ID: 33628603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial.
    Zhou J; Li L; Li X; Yu Q; Cui S; Shu K; Liu J; Liu J; Ding D; Du T
    Int J Hyperthermia; 2019; 36(1):868-875. PubMed ID: 31452420
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
    Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F
    World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer.
    Thyavihally YB; Waigankar SS; Dev P; Asari A; Pednekar AP; Athikari N; Raut A; Khandekar A; Badlani N
    Urol Ann; 2021; 13(4):424-430. PubMed ID: 34759657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.
    Chiancone F; Fabiano M; Carrino M; Fedelini M; Meccariello C; Fedelini P
    Arab J Urol; 2021 Jan; 19(1):86-91. PubMed ID: 33763253
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy.
    Doisy L; Cimier A; Adypagavane A; Walz J; Marquette T; Maubon T; Rybikowski S; Fakhfakh S; Loverde K; Mottet N; Irani J; Lechevallier E; Rossi D; Gravis G; Pignot G
    Int J Hyperthermia; 2021; 38(1):1633-1638. PubMed ID: 34775896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
    Tan WS; Prendergast A; Ackerman C; Yogeswaran Y; Cresswell J; Mariappan P; Phull J; Hunter-Campbell P; Lazarowicz H; Mishra V; Rane A; Davies M; Warburton H; Cooke P; Mostafid H; Wilby D; Mills R; Issa R; Kelly JD
    Eur Urol; 2023 Jun; 83(6):497-504. PubMed ID: 35999119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
    Thomsen JA; Nielsen Dominiak H; Lindgren MS; Jensen JB
    Scand J Urol; 2021 Aug; 55(4):281-286. PubMed ID: 34124993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection.
    Naya Y; Mikami K; Takaha N; Inoue Y; Fujihara A; Kanazawa M; Nakanishi H; Miyashita H; Ukimura O
    Medicine (Baltimore); 2018 Oct; 97(42):e12740. PubMed ID: 30334959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
    Angulo JC; Álvarez-Ossorio JL; Domínguez-Escrig JL; Moyano JL; Sousa A; Fernández JM; Gómez-Veiga F; Unda M; Carballido J; Carrero V; Fernandez-Aparicio T; García de Jalón Á; Solsona E; Inman B; Palou J
    Eur Urol Oncol; 2023 Feb; 6(1):58-66. PubMed ID: 36435738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer.
    van Valenberg H; Colombo R; Witjes F
    Int J Hyperthermia; 2016 Jun; 32(4):351-62. PubMed ID: 26905963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Marquette T; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Verde KL; Dermeche S; Gravis G; Pignot G
    Prog Urol; 2020 Jan; 30(1):35-40. PubMed ID: 31787540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
    Arends TJ; van der Heijden AG; Witjes JA
    J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
    Wen YC; Lee LM; Lin YW; Syu SH; Lin KH; Fan YC; Lee HL; Lai BCH; Shih HJ
    Int J Hyperthermia; 2021; 38(1):1627-1632. PubMed ID: 34775895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.